TuHURA BIOSCIENCES, INC./NV Additional Paid in Capital, Common Stock
TuHURA BIOSCIENCES, INC./NV (HURA) had Additional Paid in Capital, Common Stock of $176.11 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-14
- 2026-06-30: Additional Paid in Capital, Common Stock $176.11M.
- 2026-03-31: Additional Paid in Capital, Common Stock $171.57M.
- 2025-12-31: Additional Paid in Capital, Common Stock $161.78M.
- 2025-09-30: Additional Paid in Capital, Common Stock $150.87M.
| Period end | Additional Paid in Capital, Common Stock | Additional Paid in Capital, Common Stock as first filed |
|---|---|---|
| 2026-06-30 | $176.11M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $171.57M 10-Q · filed 2026-05-15 | |
| 2025-12-31 | $161.78M 10-Q · filed 2026-08-14 | |
| 2025-09-30 | $150.87M 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $146.44M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $130.38M 10-Q · filed 2025-05-15 | |
| 2024-12-31 | $125.40M 10-K · filed 2026-03-31 | |
| 2024-09-30 | $163.44M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $153.36M 10-Q · filed 2024-11-14 | $153.31M 10-K · filed 2024-10-07 |
| 2024-03-31 | $153.14M 10-Q · filed 2024-05-14 | |
| 2023-12-31 | $86.89M 10-K · filed 2025-03-31 | $145.09M 10-Q · filed 2024-02-14 |
| 2023-09-30 | $141.85M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $141.44M 10-K · filed 2024-10-07 | |
| 2023-03-31 | $141.16M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $140.57M 10-Q · filed 2023-02-14 | |
| 2022-09-30 | $138.28M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $135.57M 10-K · filed 2023-09-18 | $135.51M 10-K · filed 2022-09-27 |
| 2022-03-31 | $127.67M 10-Q · filed 2022-05-13 | |
| 2021-12-31 | $126.78M 10-Q · filed 2022-02-11 | |
| 2021-09-30 | $125.07M 10-Q · filed 2021-11-15 | |
| 2021-06-30 | $106.82M 10-K · filed 2022-09-27 | |
| 2021-03-31 | $100.83M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $93.55M 10-Q · filed 2021-02-12 | |
| 2020-09-30 | $89.78M 10-Q · filed 2020-11-12 | |
| 2020-06-30 | $65.15M 10-K · filed 2021-09-28 | $56.62M 10-K · filed 2020-09-18 |
| 2020-03-31 | $56.40M 10-Q · filed 2020-05-13 | |
| 2019-12-31 | $56.26M 10-Q · filed 2020-02-13 | |
| 2019-09-30 | $56.10M 10-Q · filed 2019-11-13 | |
| 2019-06-30 | $50.95M 10-K · filed 2020-09-18 | |
| 2019-03-31 | $47.02M 10-Q · filed 2019-05-14 | |
| 2018-12-31 | $46.83M 10-Q · filed 2019-02-11 | |
| 2018-09-30 | $43.41M 10-Q · filed 2018-11-13 | |
| 2018-06-30 | $43.20M 10-K · filed 2019-09-09 | $43.18M 10-K · filed 2018-09-24 |
| 2018-03-31 | $43.74M 10-Q · filed 2018-05-15 | |
| 2017-12-31 | $43.24M 10-Q · filed 2018-02-14 | |
| 2017-09-30 | $42.96M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $36.68M 8-K · filed 2019-06-03 | $36.67M 10-K · filed 2017-09-27 |
| 2017-03-31 | $31.51M 10-Q · filed 2017-05-12 | |
| 2016-12-31 | $30.82M 10-Q · filed 2017-02-10 | |
| 2016-09-30 | $30.52M 10-Q · filed 2016-11-10 | |
| 2016-06-30 | $28.83M 10-K · filed 2017-09-27 | |
| 2016-03-31 | $21.81M 10-Q · filed 2016-05-12 | |
| 2015-12-31 | $21.69M 10-Q · filed 2016-02-12 | |
| 2015-09-30 | $18.60M 10-Q · filed 2015-11-16 | |
| 2015-06-30 | $17.39M 10-K · filed 2016-09-13 | $17.50M 10-K · filed 2015-09-03 |
| 2015-03-31 | $17.32M 10-Q · filed 2016-05-12 | $17.46M 10-Q · filed 2015-05-15 |
| 2014-12-31 | $16.49M 10-Q · filed 2016-02-12 | $16.63M 10-Q · filed 2015-02-12 |
| 2014-09-30 | $13.85M 10-Q · filed 2015-11-16 | $13.98M 10-Q · filed 2014-11-07 |
| 2014-06-30 | $13.15M 10-K · filed 2015-11-16 | $13.29M 10-K · filed 2014-08-28 |
| 2014-03-31 | $9.75M 10-Q · filed 2014-05-15 | |
| 2013-12-31 | $8.79M 10-K · filed 2014-08-28 | |
| 2013-09-30 | $8.44M 10-Q · filed 2013-11-08 | |
| 2013-06-30 | $7.59M 10-Q · filed 2013-08-12 | |
| 2013-03-31 | $6.47M 10-Q · filed 2013-05-15 | |
| 2012-12-31 | $2.33M 10-K · filed 2014-08-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |